JP2017528454A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528454A5
JP2017528454A5 JP2017511933A JP2017511933A JP2017528454A5 JP 2017528454 A5 JP2017528454 A5 JP 2017528454A5 JP 2017511933 A JP2017511933 A JP 2017511933A JP 2017511933 A JP2017511933 A JP 2017511933A JP 2017528454 A5 JP2017528454 A5 JP 2017528454A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
pharmaceutical composition
composition according
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017511933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528454A (ja
Filing date
Publication date
Priority claimed from US14/473,339 external-priority patent/US9890200B2/en
Application filed filed Critical
Publication of JP2017528454A publication Critical patent/JP2017528454A/ja
Publication of JP2017528454A5 publication Critical patent/JP2017528454A5/ja
Pending legal-status Critical Current

Links

JP2017511933A 2014-08-29 2015-08-28 異常な線維芽細胞増殖および細胞外マトリックス沈着を特徴とする疾患、状態、またはプロセスを予防または処置するための組成物および方法 Pending JP2017528454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/473,339 2014-08-29
US14/473,339 US9890200B2 (en) 2011-04-12 2014-08-29 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
PCT/US2015/047390 WO2016033432A1 (en) 2014-08-29 2015-08-28 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Publications (2)

Publication Number Publication Date
JP2017528454A JP2017528454A (ja) 2017-09-28
JP2017528454A5 true JP2017528454A5 (https=) 2018-10-04

Family

ID=52583553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511933A Pending JP2017528454A (ja) 2014-08-29 2015-08-28 異常な線維芽細胞増殖および細胞外マトリックス沈着を特徴とする疾患、状態、またはプロセスを予防または処置するための組成物および方法

Country Status (12)

Country Link
US (2) US9890200B2 (https=)
EP (1) EP3185883A4 (https=)
JP (1) JP2017528454A (https=)
KR (1) KR20170044171A (https=)
CN (1) CN107073075A (https=)
AU (1) AU2015308761A1 (https=)
BR (1) BR112017003731A2 (https=)
CA (1) CA2958085A1 (https=)
MX (1) MX2017002476A (https=)
RU (1) RU2017110093A (https=)
SG (1) SG11201701135WA (https=)
WO (1) WO2016033432A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2016112292A1 (en) * 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
RU2017135072A (ru) * 2015-03-12 2019-04-10 Мори Матрикс, Инк. Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого
CN112920256B (zh) * 2019-11-21 2022-08-19 上海医药工业研究院 一种治疗哮喘的生物肽及其应用
MX2024008704A (es) 2022-01-14 2024-07-22 Shanghai Hansoh Biomedical Co Ltd Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este.

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
DE3682457D1 (de) 1985-07-30 1991-12-19 Glaxo Group Ltd Geraet zur verabreichung von medikamenten an patienten.
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
JPH07506252A (ja) 1992-04-24 1995-07-13 エス・アール・アイ・インターナシヨナル 真核細胞内でのイン・ビボ相同配列ターゲッティング
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP0733059B1 (en) 1993-12-09 2000-09-13 Thomas Jefferson University Compounds and methods for site-directed mutations in eukaryotic cells
AU692839B2 (en) * 1994-02-17 1998-06-18 American Home Products Corporation Substituted biphenyl derivatives as phosphodiesterase inhibitors
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
ES2261195T3 (es) 1999-04-05 2006-11-16 Mannkind Corporation Metodo de formacion de particulas finas.
ES2569916T3 (es) 1999-06-29 2016-05-13 Mannkind Corporation Formulaciones farmacéuticas que comprenden insulina complejada con una dicetopiperazina
WO2003090682A2 (en) 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US20040219142A1 (en) 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN101014321A (zh) 2004-08-23 2007-08-08 曼金德公司 5型磷酸二酯酶抑制剂的肺部给予
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US20080057129A1 (en) * 2006-04-03 2008-03-06 Lerner E I Drug microparticles
DK2617431T3 (en) 2007-01-10 2017-07-10 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and applications therefor
US8063094B2 (en) 2007-02-08 2011-11-22 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US20080282320A1 (en) 2007-05-11 2008-11-13 Denovo Andrew Security Compliance Methodology and Tool
WO2009021137A2 (en) 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
AU2013202108B2 (en) * 2008-12-10 2015-12-24 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
EP2378875B1 (en) 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US20130115256A1 (en) 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
KR101862291B1 (ko) 2011-04-12 2018-05-29 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2014533235A5 (https=)
RU2013150249A (ru) Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса
JP2017528454A5 (https=)
JP6889201B2 (ja) Il−4および/またはil−13のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法
JP2018501201A5 (https=)
US20130216608A1 (en) Airway Administration of Angiogenesis Inhibitors
JP2014169332A (ja) 肺疾患を処置するためのモノクローナル抗体の霧状化
JP2002539072A5 (https=)
JP2017509633A5 (https=)
JP2015505303A5 (https=)
JP2022500078A5 (https=)
JP2016516016A5 (https=)
RU2017110093A (ru) Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса
JP2004500844A (ja) Tweakアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
Li et al. Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization
CA2558212A1 (en) Interferon-beta for anti-virus therapy for respiratory diseases
JP2020501510A5 (https=)
CN103429610A (zh) 用于抑制炎症的肽
CN106075401A (zh) 白介素35在制备治疗自身免疫性皮肤病药物中的用途和治疗药物以及IL‑35‑Fc融合蛋白
RU2016140332A (ru) Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл)
CN102584976A (zh) 一种人血清淀粉样蛋白a1及其制备方法和应用
JP2002515459A (ja) 喘息および他のアレルギー性症状を治療するための方法およびtnf−rii(p75)アゴニストを含む組成物の使用
CN121337989A (zh) 靶向刺激免疫分子在制备治疗器官纤维化疾病药物的用途
Laurina et al. Growth factors/cytokines/defensins and apoptosis in periodontal pathologies
CN117209612A (zh) 融合蛋白及其应用